On March 22, 2011 the U.S. Supreme Court handed down a decision which is likely to have serious repercussions for companies in the bio/pharma tech space. In MATRIXX INITIATIVES, INC., ET AL. v. SIRACUSANO ET AL., the Court rejected Matrixx argument that reports regarding the adverse effect of Zicam, its leading revenue generating product, were not statistically significant and therefore not material.
Noting that the analysis of materiality under the securities laws in fact specific, the Court appears to have relied heavily on two factors:
1. The methodologies and requirements ...
Blog Editors
Recent Updates
- Video: FMLA and FLSA Compliance in 2026—New DOL Opinion Letters and Emerging Risks - Employment Law This Week
- Federal Shutdowns and Workplace Law: Navigating Legal Uncertainty
- Epstein Becker Green’s Employment Law 2025 Highlight Reel: 10 Issues That Dominated—and What’s Lurking in 2026
- Video: Employment Law in 2026: What to Expect - Employment Law This Week
- When Your Data Sets Your Price: New York Takes on Algorithmic Pricing